API | clodronate disodium

clodronate disodium Report issue

Small molecule Experimental

AACT ChEMBL PubChem

Active Ingredient History

NOW

Clodronic acid (INN) or clodronate disodium (Na2CH2Cl2O6P2) (USAN) is a first generation (non-nitrogenous) bisphosphonate. It is an anti-osteoporotic drug approved for the prevention and treatment of osteoporosis in post-menopausal women and men to reduce vertebral fractures, hyperparathyroidism, hypercalcemia in malignancy, multiple myeloma and fracture related pain because of its potent anti-inflammatory and analgesic effects shown as a reduction in inflammatory markers like IL-1β, IL-6, and TNF-α. ^Wikipedia

Chemistry

SMILES: [Na+].[Na+].OP(=O)([O-])C(Cl)(Cl)P(=O)(O)[O-]
InChIKey: HJKBJIYDJLVSAO-UHFFFAOYSA-L
Mol. Mass: 288.86
ALogP: 0.43 Partition coefficient
ChEMBL Molecule:
clodronate disodium

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

177501 | bonefos | clodronate disodium | disodium clodronate | zk-00091106

Organizations (17)

Research & Development (17)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)

Breast Neoplasms (Phase 3)

Hip Injuries (Phase 1)

Osteoporosis, Postmenopausal (Phase 3)

Pain (Phase 3)

Prostatic Neoplasms (Phase 3)

Quality of Life (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 5
# of Trial Organizations: 17

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue